DE69739482D1 - Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen - Google Patents

Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen

Info

Publication number
DE69739482D1
DE69739482D1 DE69739482T DE69739482T DE69739482D1 DE 69739482 D1 DE69739482 D1 DE 69739482D1 DE 69739482 T DE69739482 T DE 69739482T DE 69739482 T DE69739482 T DE 69739482T DE 69739482 D1 DE69739482 D1 DE 69739482D1
Authority
DE
Germany
Prior art keywords
neoplasms
insecticide
prophylaxis
therapy
formulations containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739482T
Other languages
English (en)
Inventor
Elizabeth Shanahan-Prendergast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69739482D1 publication Critical patent/DE69739482D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A61K35/583—Snakes; Lizards, e.g. chameleons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01004—Phospholipase A2 (3.1.1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04011—Phosphoinositide phospholipase C (3.1.4.11)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DE69739482T 1996-09-11 1997-09-10 Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen Expired - Lifetime DE69739482D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2517996P 1996-09-11 1996-09-11
PCT/IB1997/001091 WO1998010776A1 (en) 1996-09-11 1997-09-10 Therapeutic formulations containing venom or venom anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms

Publications (1)

Publication Number Publication Date
DE69739482D1 true DE69739482D1 (de) 2009-08-13

Family

ID=21824505

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739482T Expired - Lifetime DE69739482D1 (de) 1996-09-11 1997-09-10 Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen

Country Status (10)

Country Link
US (5) US20030175277A1 (de)
EP (1) EP1019068B1 (de)
AT (1) ATE435023T1 (de)
AU (1) AU741943B2 (de)
CA (1) CA2265631A1 (de)
DE (1) DE69739482D1 (de)
ES (1) ES2329529T3 (de)
HK (1) HK1028545A1 (de)
PT (1) PT1019068E (de)
WO (1) WO1998010776A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69934325T2 (de) * 1998-09-08 2007-07-05 Biomolecular Products, Inc., Byfield Zusammenstellungen zur erhöhung der darmabsoption von fetten
AU1534900A (en) * 1998-11-12 2000-06-05 Analytica Ltd A method of treatment
KR100831118B1 (ko) * 2000-05-26 2008-05-20 심포젠 에이/에스 알레르기를 치료하기 위한 재조합 폴리클로날 항체 또는정제된 폴리클로날 항체
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
MXPA03002934A (es) * 2000-10-10 2004-05-04 Univ North Carolina Composiciones y metodos para aumentar la permeabilidad paracelular a traves de las barreras epiteliales y endoteliales.
WO2002085391A1 (es) * 2001-04-24 2002-10-31 Luis Alberto Costa Uso de una fosfolipasa a2 para la preparacion de composiciones farmaceuticas y/o cosmeticas para la prevencion y/o el tratamiento local y/o sistemico de enfermedades y/o procesos provocados por patogenos intra y extracelulares que expresen fosfolipidos de membrana
DE10330712A1 (de) * 2003-07-08 2005-01-27 Toximed Gmbh Pharmarzeutischer Wirkstoff gegen Kolonkarzinome und andere Tumorarten
DE10342747A1 (de) * 2003-09-16 2005-04-28 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Melanome

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189471A (en) 1978-07-11 1980-02-19 Merck & Co., Inc. Immunologic glycolipid adjuvants
EP0064366A1 (de) 1981-04-29 1982-11-10 Beecham Group Plc Pharmazeutische Zusammensetzungen
ES2054668T3 (es) * 1986-05-19 1994-08-16 Ventech Research Inc Composicion farmaceutica util para el tratamiento de carcinomas y otras enfermedades y un proceso para la preparacion del componente activo y de la composicion farmaceutica.
US5053492A (en) * 1986-08-07 1991-10-01 Board Of Regents, The University Of Texas System Immunopurification using monoclonal antibodies to Mojave toxin
US5164196A (en) * 1987-05-19 1992-11-17 Ventech Research, Inc. Crotoxin complex as cytotoxic agent
US5019508A (en) * 1987-08-27 1991-05-28 Biotechnology Research Partners, Ltd. Synovial phospholipases
US4822608A (en) * 1987-09-14 1989-04-18 Vespa Laboratories, Inc. Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom or proteinaceous or polypeptide components thereof
FR2623508B1 (fr) * 1987-11-20 1990-04-20 Commissariat Energie Atomique Proteine basique denommee phospholipase a2 isolee de venin de serpent de la famille des elapides et sa sequence en amino-acides, derives et fragments de ladite proteine, leur procede d'obtention, compositions therapeutiques et agents de diagnostic contenant ladite proteine et/ou ses derives et/ou ses fragments
US5622832A (en) * 1990-02-28 1997-04-22 Genetics Institute, Inc. Arachidonic acid releasing phospholipase A2 enzyme and methods of use
JP2984029B2 (ja) * 1990-05-30 1999-11-29 塩野義製薬株式会社 膜型ホスホリパーゼａ▲下２▼を認識するモノクローナル抗体および膜型ホスホリパーゼａ▲下２▼の免疫測定法
US5178864A (en) * 1990-08-14 1993-01-12 Mit Lipoprotein removal by soluble enzymes
DE4142552A1 (de) 1991-12-21 1993-06-24 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen die typ i phospholipase a(pfeil abwaerts)2(pfeil abwaerts) als entzuendungshemmendes therapeutikum
US5565431A (en) * 1994-06-20 1996-10-15 Lipps; Binie V. Cancer cell inhibitors and method
FR2722692B1 (fr) 1994-07-20 1997-03-21 Rhone Poulenc Rorer Sa Medicament a base de phospholipase a2 de venin d'abeille
US5698583A (en) * 1994-11-15 1997-12-16 Crescenti; Ernesto J.V. Oligoelements and phospholipase A2 immuno-enhancer compositions, preparation thereof, and use thereof

Also Published As

Publication number Publication date
PT1019068E (pt) 2009-10-08
EP1019068B1 (de) 2009-07-01
EP1019068A1 (de) 2000-07-19
ATE435023T1 (de) 2009-07-15
ES2329529T3 (es) 2009-11-26
US8580744B2 (en) 2013-11-12
US20040131632A1 (en) 2004-07-08
US20080044431A1 (en) 2008-02-21
US20100196459A1 (en) 2010-08-05
WO1998010776A1 (en) 1998-03-19
CA2265631A1 (en) 1998-03-19
AU741943B2 (en) 2001-12-13
HK1028545A1 (en) 2001-02-23
US20030175277A1 (en) 2003-09-18
AU4132397A (en) 1998-04-02
US20120258115A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
DE3382458D1 (de) Haarwuchsmittel.
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
PT758900E (pt) Toxina botulinica para a reducao da dor de cabeca devida a enxaqueca
DK0880350T3 (da) Behandling af dissemineret sklerose
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
DE69424777T2 (de) 3,4-diarylchromane zur behandlung von dermatitis
ATE267583T1 (de) Arzneizubereitungen zur behandlung sexueller funktionsstörungen
MX9401294A (es) Derivados de azolona sustituida
DE69739482D1 (de) Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen
NO912435D0 (no) Farmasoeytiske preparater.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DK0817646T3 (da) Fremgangsmåder til behandling af inflammation og præparater derfor
SE9601395D0 (sv) New therapeutic treatment 1
NO984446L (no) FremgangsmÕte for behandling av smerte
BR0115215A (pt) Método para o tratamento de inflamações
ATE149840T1 (de) Behandlung von leberkrebs
ES2104223T3 (es) 2-((2-(n-isobutil-n-metil)amino)-bencilsulfinil)bencimidazol como agente antimicrobiano contra helicobacter pylori.
DE69729201T2 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
DK0673646T3 (da) Anvendelse af deoxyspergualin til fremstilling af et lægemiddel til behandling af inflammatorisk-hyperreaktive sygdomme
SE8306384L (sv) Farmaceutisk komposition
NO984198L (no) FremgangsmÕte for behandling av aggresjon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition